权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

プロテオミクスによる膵癌特異抗原に対する新規自己抗体の同定

通过蛋白质组学鉴定针对胰腺癌特异性抗原的新型自身抗体

基本信息

批准号：
18591530
负责人：
宮本好晴
金额：
$ 1.66万
依托单位：
Osaka Medical College
依托单位国家：
日本
项目类别：
Grant-in-Aid for Scientific Research (C)
财政年份：
2006
资助国家：
日本
起止时间：
2006 至无数据
项目状态：
已结题

来源：
https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-18591530/
关键词：
膵癌特異抗原自己抗体 PANC-1

项目摘要

本研究は膵癌発現蛋白と特異的に結合する患者血清中の自己抗体を標的として膵癌特異抗原を選択的に検索・同定することを目的とした。次に述べる(1)〜(4)までの4段階に沿って研究を進める計画とした。(1)2次元電気泳動法、ウェスタンブロットおよびプロテオーム手技を用いて汎用性株細胞ヒト膵臓癌(PANC-1:(株)大日本住友製薬)発現蛋白に特異結合する新規自己抗体を膵癌患者血清中より同定する。(2)自己抗体に対する抗原蛋白のmRNAを細胞株より抽出、cDNAを合成し大腸菌に導入する。抗原蛋白を大量合成しELIZA法を確立する。(3)膵癌、膵炎(非膵癌疾患)および健常者を対象に測定し、新たな癌マーカーとしての有用性を検討する。(4)臨床へのフィードバックを目的に外科切除された膵癌標本(癌部、非癌部)を用いて遺伝子発現、免疫染色等により抗原蛋白の機能解析を行い検出された自己抗体の治療への応用も検討する。まず前記(1)の予備研究として、ヒトゲノム・遺伝子解析研究に関する倫理指針(平成13年3月29日文部科学省・厚生労働省・経済産業省告示第1号)及びヒトゲノム・遺伝子解析研究に関する倫理指針の施行等について(平成13年3月29日付け文部科学省研究振興局長・厚生労働省大臣官房厚生科学課長・経済産業省製造産業局長連名通知)を遵守して採取保存された健常人および食道癌患者の血清を用いて、2次元電気泳動法、ウェスタンブロットおよびプロテオーム手技による検討を行った。その結果、食道癌患者血清において新たな癌マーカー候補「ペルオキシレドキシン6」を見出し報告した。引き続いて、汎用性株細胞ヒト膵臓癌(PANC-1)発現蛋白に特異結合する新規自己抗体を膵癌患者血清中より同定するマーカー候補検索を行なった。しかし研究代表者が病気のため長期療養に入ることになるため、平成18年10月1日より研究廃止とした。

The purpose of this study is to identify the specific antigen of cancer specific antigen in the serum of patients with cancer protein specificity. This is the second description of paragraph 4 of (1) ~ (4). Along the way, the study will be carried out to further the planning process. The main results were as follows: (1) the two-step swimming method was used to detect the homology of protein in the serum of patients with cancer by using the sex strain (PANC-1: (strain) Sumitomo of Japan). (2) the autoantibody antigen protein mRNA was extracted from the cell line and cDNA was used to synthesize the bacteria into the cell. Antigen proteins were synthesized in large quantities and confirmed by ELIZA method. (3) cancers, inflammatory diseases (non-cancerous diseases), patients with normal conditions, patients with normal cancers, and patients with new cancers. (4) the cancer marker (cancer part, non-cancer part) of surgical resection can be analyzed by immunostaining and other anti-tumor antigen protein machines. Before (1) to prepare for research, An analytical study of the Ministry of Education, Culture, Science and Technology (notice No. 1 of the Ministry of Health, Education, Science and Technology, Ministry of Education, Culture, Science and Technology, March 29, 13) and the Ministry of Education, Culture, Science and Technology, Ministry of Education, Culture, Science and Technology, Ministry of Education, Culture, Science and Technology, Ministry of Education, Culture, Science and Technology, Ministry of Education, Culture, Science and Technology, Ministry of Education, Culture, Science and Technology, Ministry of Education, Culture, Science and Technology, Ministry of Health and Health, Ministry of Education, Culture, Science and Technology, Ministry of Education, Culture, Science and Technology, Ministry of Health, Ministry of Education, Ministry of Health, Ministry of Health, Ministry of Education, Culture, Science and Technology, Ministry of Health and Health The Chief Executive of the Ministry of Industry and Industry has been informed by the contact name of the Director of the Ministry of Health and Industry) to observe the use of the serum of patients with esophageal cancer in normal people. The second step is the swimming method, which means that you can do the swimming in two times. The results showed that there was a report in the serum of patients with esophageal cancer. The serum samples of cancer patients were detected by immunocytochemistry (PANC-1) protein specific assay combined with novel autoantibodies. The representative of the research group, who is sick and sick, has been involved in the study for a long time, Pingcheng, October 1, 18.